anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Weekly 60 min. group meetings, lead by trained KSRE staff, (12-15 participants) will be held by Zoom over 6 months followed by monthly 60 min. group meetings for the later 6 months. Approximately 5 min prior to the meeting time (typically early evening) participants will receive call in information to join the group meeting by video conferencing or phone.
Subarachnoid hemorrhage (SAH) is a neurological disorder that severely damages the brain and causes cognitive impairment. MicroRNAs are critical regulators in a variety of neurological diseases. MiR-497-5p has been found to be downregulated in the aneurysm vessel walls obtained from patients with aneurysmal subarachnoid hemorrhage, but its functions and mechanisms in SAH have not been reported. Therefore, this study was designed to investigate the effect of miR-497-5p and its related mechanisms in SAH. We established an in vitro SAH model by exposing PC12 cells to oxyhemoglobin (oxyHb). We found that miR-497-5p was downregulated in SAH serum and oxyHb-treated PC12 cells, and its overexpression inhibited the oxyHb-induced apoptosis, inflammatory response and oxidative stress via activation of the Nrf2 pathway. Mechanistically, the targeting relationship between miR-497-5p and Otx1 was verified by luciferase reporter assays. Moreover, Otx1 upregulation abolished the protective effects of miR-497-5p upregulation against oxyHb-induced apoptosis, inflammation and oxidative stress in PC12 cells. Collectively, our findings indicate that miR-497-5p could inhibit the oxyHb-induced SAH damage by targeting Otx1 to activate the Nrf2/HO-1 pathway, which provides a potential therapeutic target for SAH treatment.
PURPOSE: The aim of this study was to analyze the tissue quality and outcomes of corneal transplants from donor corneal tissues harvested from drowning victims.
METHODS: This retrospective study was conducted on corneal tissues harvested from drowning victims between March 2018 and September 2022. Details of the tissue quality and outcomes after keratoplasty were collected from the eye bank and outpatient records.
RESULTS: Thirty-four donor corneas were collected from drowning victims during the study period. The mean age of the donors was 37.1 ± 20.3 years. The mean donor-to-preservation time was 4.9 ± 2.6 hours. The mean endothelial cell density was 3025 ± 271 cells/mm 2 . Twenty donor corneas (58.8%) were used at our institute, 2 were stored in glycerol for future use, and 12 were transported to other transplant centers. The overall utilization was 94.1% (32/34 corneas). Of the 20 corneas used at our institute, 17 were used for optical grafts and 3 for therapeutic indications. Of the 17 optical grafts, 10 were used for optical penetrating keratoplasty, 6 for endothelial keratoplasty, and 1 for anterior lamellar keratoplasty. The most common indication for keratoplasty was regrafting the previously failed grafts (25%). None of the transplanted eyes developed an infection in the immediate postoperative period. Eight eyes had clear grafts after 3 months. Of the 12 tissues transferred to other keratoplasty centers, 10 were used for optical grafts and 2 for therapeutic/tectonic grafts.
CONCLUSIONS: Donor corneas retrieved from drowning victims may be considered safe for transplantation. The postoperative outcomes of the tissues obtained from these donors were satisfactory. Hence, these donor corneas can be optimally used in routine transplantation procedures.
We propose to explore the effects of GLP-1 agonism on brain structure and function. We hypothesize that the administration of GLP-1 agonists may result in increased connectivity in the executive control network. Multiple clinical trials with pharmacological agents, as well as cognitive therapy, have reported that measurements of brain structure and function are correlated with cognitive performance, indicating that they are a valid biological correlate of cognitive function. To assess this hypothesis we will recruit a clinical population, represented by individuals with a measurable impairment in executive function, wherein the target of our proposed intervention was shown to be altered.

We are currently not in a position to sufficiently homogenize subgroups of adults with mood disorder on the basis of any single or combinatorial biomarkers. It is also unlikely that alterations in GLP-1 receptor function, and the proposed model herein, is sufficiently explanatory to all sub-populations of adults with mood disorders. Instead, we propose that adults with mood disorders, who have co-existing metabolic disorders (e.g. type 2 diabetes mellitus), would be more likely to have a brain illness that is influenced by (i.e. cause, consequence or both) alterations in cellular bioenergetics. Moreover, convergent evidence suggest that GLP-1 receptor function may be, at least partially, dependent on glucose levels and/or insulin sensibility. It is a separate, yet testable, hypothesis that subpopulations enriched on the basis of having metabolic comorbidity (i.e. insulin resistance) may be more responsive to an intervention that targets a metabolic pathway.

We plan to test the effects of adjunctive liraglutide on executive function. We will select a subpopulation of patients, with a mood disorder and impairment in executive function, as defined by a below-average (i.e. 1 standard deviation below norm) performance in the Trail Making Test-B (TMTB). Furthermore, we plan to recruit two groups of patients, with and without insulin resistance, as defined by a homeostatic model assessment for insulin resistance (HOMA-IR) above 2.5, which will allow a comparison of the effects of liraglutide in a metabolically heterogeneous population.
The Dyadic Life Review Arm (DLR) consists of 8 sessions delivered by a trained licensed clinician. Each session facilitates a recall of each phase of life. The patient and caregiver will each be asked structured questions to prompt reminiscence of memories from that phase of life. Interventionists are able to use clinical judgment to prompt further or ask follow-up questions or reflections. Additionally, the patient and caregiver will be asked to respond to the other dyad member's memory or reflection. Each session will have flexibility for clinical judgement.
Method for purifying a micoorganism cells lytic enzyme by lowering the pH value of the aqueous solution containing the micoorganism cells lytic enzyme and proteases within a range of about 3.0 to 1.0 with an acid and, if necessary, by neutralizing the acidic mixture within a range of pH about 4.0 to 8.0 with an alkali and then filtering off the resulting precipitates and thereby removing off the proteases contaminated in the micoorganism cells lytic enzyme; the microorganism cells lytic enzyme being produced by cultivating a microorganism of the genus Streptomyces, e.g. S-1 strain (Streptomyces diastatochromogenes; ATCC No. 21481), H-191 strain (Streptomyces farinosus; ATCC No. 21482), H-402 strain (Streptomyces griseus var. H-402; ATCC No. 21483) and B-1829 strain (Streptomyces globisporus; ATCC No. 21553).
The invention relates to an external patch containing anastrozole and a preparation method thereof. The external preparation uses anastrozole as a main drug, and is used for treating breast cancer. The external patch containing anastrozole is absorbed in a percutaneous manner, is uniform in drug release and mild and durable in action. One patch can be continuously used for 7 days. The patch directly acts on skin without passing through gastrointestinal tracts, so that the first pass effect of liver can be avoided, adverse response is reduced, and the occurrence rate of adverse responses is reduced. The external patch has good patient compliance, and is convenient to use and carry.
The invention discloses a rehabilitation motion mode identification and parameter solving method based on a support vector machine. And then carrying out support vector machine model training by using the data of the training set. And finally, testing the trained support vector machine model by using the data of the test set to obtain a calculation error, and loading the model into portable acquisition equipment. If the error is less than 5%, the model is used for motion pattern identification and motion parameter calculation, and if the error is more than or equal to 5%, the model is updated and reminded to the wearer, and each is reminded. Individual wearers perform differential model training. The invention avoids the inaccuracy of the motion model based on the traditional motion parameter calculation method.
Sham stimulation was identical to the 40Hz stimulation, except that the acoustic and electric stimulation were ramped down after 0.5 min to remain turned off for the remaining 39.5 min. Sham stimuli are applied for 40min/day, for a total of 5 days.
Stress management treatment for 10 weeks Participants randomized to The Stress Management Treatment will receive 10 weeks of stress managemen including relaxation technics, standard life style advice regarding physical activity, sleep and and standardized AF-information in line with current guidelines for AF. Therapist support is provided at least once weekly through the platform developed for the purpose. Therapists are trained CBT-psychologists.
Patients with APS type 2: - with adrenal insufficiency for 50% of them. - a delay of two weeks after stopping antifungal or antibiotic treatment in patients is to be respected.
Tramadol hydrochloride is a centrally acting synthetic analgesic in an extended-release formulation. The chemical name is (±)cis-2-[(dimethylamino) methyl]-1-(3-methoxyphenyl) cyclohexanol hydrochloride. Its structural formula is:   


Figure 1

The molecular weight of tramadol hydrochloride is 299.84. It is a white, crystalline powder that is freely soluble in water and methanol, very slightly soluble in acetone and has a pKa of 9.41. The n-octanol/water log partition coefficient (logP) is 1.35 at pH 7. Tramadol hydrochloride extended-release tablets contain 100 mg, 200 mg or 300 mg of tramadol hydrochloride, USP in an extended-release formulation. The tablets are white in color and contain the inactive ingredients pregelatinized maize starch, hypromellose, mannitol, magnesium stearate, cellulose acetate and polyethylene glycol.

Imprinting ink contains, shellac glaze, iron oxide black, N-butyl alcohol, ammonium hydroxide and propylene glycol.
PURPOSE:To provide an adhesive sheet for medical use which can be removed easily by water at a low temperature, while having an adhesive force to prevent the removal owing to a perspiration or an exudation from an wound on the skin. CONSTITUTION:The objective adhesive composite for skin consists of 10 to 90 pts.wt. of a water-insoluble and temperature-responsible high polymer compound whose transition temperature to water is 4 to 34 deg.C, and exhibiting a water absorbing property at a temperature lower than the transition temperature 90 to 10 pts.wt. of an adhesive high polymer. The composite is applied on a base material to form an adhesive sheet for medical use. As a result, the adhesive sheet maintains the adhesive property without losing the adhesive force, and it can be peeled easily from the surface of the skin without generating a pain, a damage of the skin tissue or a depilation.
Participants will perform constant power output tests at four separate, fixed intensities to exhaustion on a cycle ergometer on separate days. These exhaustive, constant power tests will be preceded by 3 minutes of light cycling, 6 minutes of high intensity cycling, 7 minutes of rest and 3 minutes of light cycling.
Patients will be randomly assigned to receive 2 single doses of ivermectin at 200 µg/kg 2 weeks apart versus ivermectin at 200 µg/kg for 2 consecutive days. Patients will be randomized 50-50 to the study groups using the date of birth and a random number table. All patients will be interviewed to obtain the medical history during the initial evaluation. Patients will be asked about demographic data on a questionnaire written in English and Spanish. Physical exams, baseline blood cell counts, serum chemistries, HTLV-1(human T-cell lymphotrophic virus) serology, an IgE (immunoglobulin E), a stool sample for O \&P, and a pregnancy test will be performed as routine care all patients currently receive in our clinic.Procedures: Strongyloides serology will be performed in the parasitology laboratory of Jacobi Hospital with an in-house ELISA that uses a 31-kDA(kilodalton) recombinant protein antigen (termed NIE) derived from L3 stage of S. stercoralis and purified from E. coli BL21 containing pET30b plasmid. Once the in-house serology is performed serum will be banked, so it can be available to run in paired with samples taken during follow up visits. Blood samples will be also collected and sent to the Laboratory of Parasitic Diseases (LPD) at the NIAID- National Institutes of Health (NIH) to perform other serological techniques including the Luciferase Immunoprecipitation Systems Assay (LIPS) based on NIE and the recombinant antigen S. stercoralis immunoreactive antigen (SsIR). In addition, stools will be collected from all patients and will be fixated in SAF(sodium acetate, acetic acid and formalin), to check for Strongyloides stercoralis larvae. If possible, fresh stool will be obtained to check for larvae using the Baermann technique and an aliquot will be frozen and sent to the NIH for DNA extraction and PCR(polymerase chain reaction as).
Wheat leaf rust, caused by Puccinia triticina (Pt), remains a constant threat to wheat production worldwide. Deployment of race-specific leaf rust (Lr) resistance genes in wheat provides effective protection against leaf rust, but often leads to selective pressures that drive the rapid emergence of new virulent Pt isolates in nature. However, the molecular mechanisms underlying the evasion of Lr-delivered resistance by leaf rust remain largely unknown. Here, we identify an avirulence gene AvrLr21 in Pt that triggers Lr21-dependent immune responses. BSMV (Barley stripe mosaic virus)-mediated host-induced gene silencing assay shows that silencing AvrLr21 compromises Lr21-mediated immunity. AvrLr21 interacts directly with Lr21 protein to induce a hypersensitive response in tobacco leaves. The evolved Lr21-breaking Pt isolates can suppress Lr21-mediated immunity. Our data provide a basis for studying the molecular determinants in Pt-wheat incompatible interaction and monitoring natural Pt populations to prioritize the deployment of Lr resistance genes in the field.
1292873 Elixirs CIBA GEIGY AG 6 Jan 1970 [29 Jan 1969] 530/70 Heading A5B Pharmaceutical elixirs comprise, per 100 mls, 10-20g ethanol, 75-15g aliphatic polyol (e.g. sorbitol) and/or a sugar, up to 25g of 1, 2-propane-diol being counted as part of the polyol, and/or up to 5g of sodium salicylate whereby the 0.4 gold amount of said 1, 2- propane-diol when present plus the amount of sodium salicylate when present is at least 3g and 0.2 to 3g of a monosodium pamoate salt of a therapeutic base having in its structure a tricyclic ring system with a substituent having 1 or 2 basic nitrogen atoms attached to the middle ring, the remainder being water. Suitable therapeutic bases are phenothiazines, e.g. thioridazine, and dibenz [b, f] azepines and dibenz [a, d] cycloheptanes, e.g. imipramine desipramine, clomipramine, opipramol, amitryptyline having sedative and antidepressant activity. Reference is also made to antitussives and antiinfective agents. The pamoate salts may be prepared in situ by combining two parts of the final elixir one containing a conventional acid addition salt of the therapeutic base and the other the theoretical quantity of pamoic acid monosodium salt.
The invention relates to a medicament for preventing and treating hepatitis B and a preparation method thereof. The medicament consists of a first party and a second party. The first party is prepared from the following raw materials by mass: 120g to 180g of lightyellow sophora root, 80g to 120g of radix berberidis, and 30g to 70g of indigowoad root. The second party is prepared from the following raw materials by mass: 5g to 30g of Chinese magnoliavine fruit, 45g to 75g of Chinese aralia bark and root-bark, 30g to 50g of virgate wormwood herb, 30g to 60g of gynostemma pentaphyllum, 45g to 150g of radix astragali seu hedysari, 30g to 60g of glossy ganoderma, 45g to 75g of cassia seed, 30g to 60g of boxthorn and 30g to 75g of Chinese date. The medicament for preventing and treating the hepatitis B overcomes the defects of the conventional therapeutic medicament, has effects on strengthening the immunity, smoothing the liver, protecting the gallbladder, inhibiting virus replication, killing harmful bacteria and the like, and not only has short treatment period and good treatment effect, but also has low price without obvious toxic and side effects by clinical application. The medicament of the invention can be used as an essential medicament for preventing and treating the hepatitis B. The medicament can be prepared into medicinal granules, capsules or troches, and can be taken conveniently.
It was applied conventional TENS with FIV effect, frequency of 100 Hertz, a pulse width of 60μs and intensity adjusted according to the individual baseline for each patient without causing muscular contraction. The electrodes were arranged in a cross shape in the paravertebral region (levels T12-L1 and L5 - S1). Treatment consisted of 10 sessions (2x / week / 5 weeks), with each session lasting 30 '.
<P>PROBLEM TO BE SOLVED: To provide a crosslinking polymer composition which carries out the adhesion between the surfaces of natural organizations and achieves the reinforcement of tissues, and to provide a usage thereof.  <P>SOLUTION: The crosslinking polymer composition comprises a first synthetic polymer having a plurality of nucleophilic groups which are to be bonded with covalent bonds to a second synthetic polymer having a plurality of electrophilic groups. The first synthetic polymer is preferably a synthetic polypeptide or a polyethylene glycol which is so modified as to contain a plurality of nucleophilic groups. The second synthetic polymer may be a hydrophilic or hydrophobic synthetic polymer, and contains two or more electrophilic groups or is made for a derivative to contain them. This composition may contain still more other components. Additionally, by using the crosslinking polymer composition, a method for achieving the adhesion between a first surface and a second surface, one for carrying out the tissue reinforcement, one for preventing the surgical adhesion from forming and one for coating the surface of a synthetic implant, are also provided.  <P>COPYRIGHT: (C)2004,JPO&NCIPI
This study is a single center double-blind randomized sham-controlled trail.We aims to recruit 52 mild traumatic brain injury participants with symptoms for more than 10 days.Clinical assessments include Post-Concussion Symptom Scale (PCSS) scores, and the amount of medication used for symptom management. These 52 participants will be 1:1 randomly allocated into two groups (1) sham FSM with symptom management medication and (2) True FSM with symptom management medication. The treatment period will last two weeks, with a total of six therapy sessions. Following treatment, a four-week observation period will be conducted. The primary outcome measurement will be changes in the Post-Concussion Symptom Scale (PCSS) scores, recorded at baseline, after the third treatment session, at the end of treatment, and at the end of the observation period. Secondary outcome measures will include the amount of medication used for symptom management. The safety evaluated index is the adverse event rate for two groups. These assessments aim to evaluate the therapeutic benefits of FSM for mild traumatic brain injury.
Central robust network functional rearrangement is a characteristic of several neurological conditions, including chronic pain. Preclinical and clinical studies have shown the importance of pain-induced dysfunction in both orbitofrontal cortex (OFC) and nucleus accumbens (NAc) brain regions for the emergence of cognitive deficits. Outcome information processing recruits the orbitostriatal circuitry, a pivotal pathway regarding context-dependent reward value encoding. The current literature reveals the existence of structural and functional changes in the orbitostriatal crosstalk in chronic pain conditions, which have emerged as a possible underlying cause for reward and time discrimination impairments observed in individuals affected by such disturbances. However, more comprehensive investigations are needed to elucidate the underlying disturbances that underpin disease development. In this review article, we aim to provide a comprehensive view of the orbitostriatal mechanisms underlying time-reward dependent behaviors, and integrate previous findings on local and network malplasticity under the framework of the chronic pain sphere.
TGF-β is thought to be involved in the physiological functions of early organ development and pathological changes in substantial organ fibrosis, while studies around adipose tissue function and systemic disorders of glucolipid metabolism are still scarce. In this investigation, two animal models, aP2-SREBP-1c mice and ob/ob mice, were used. TGF-β pathway showed up-regulated in the inguinal white adipose tissue (iWAT) of the two models. SB431542, a TGF-β inhibitor, successfully increased inguinal white adipocyte size by more than 1.5 times and decreased the weight of Peripheral organs including liver, Spleen and Kidney to 73.05%/62.18%/73.23% of pre-administration weights. The iWAT showed elevated expression of GLUTs and lipases, followed by a recovery of circulation GLU, TG, NEFA, and GLYCEROL to the wild-type levels in aP2-SREBP-1c mice. In contrast, TGF-β inhibition did not have similar effects on that of ob/ob mice. In vitro, TGF-β blocker treated mature adipocytes had considerably higher levels of glycerol and triglycerides than the control group, whereas GLUTs and lipases expression levels were unchanged. These findings show that inhibiting the abnormally upregulated TGF-β pathway will only restore iWAT expansion and ameliorate the global metabolic malfunction of glucose and lipids in lipodystrophy, not obesity.